



14 November 2022

**OMEGA DIAGNOSTICS GROUP PLC**  
("Omega" or the "Company" or the "Group")

**Partnership agreement with Nutrigenomics Software Provider**  
*Creating detailed lifestyle and dietary guidance reports from genetic data*

Omega (AIM: ODX), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, announces that it has signed heads of terms with regards to a partnership agreement (the “**Agreement**”) with a leading nutrigenomics software provider to develop and commercialise a bespoke DNA report for Omega.

The report will be a unique and proprietary software tool which will expand the Company’s product portfolio in line with its stated strategy to broaden its menu of tests. By understanding the relationship between nutrients, diet, and gene expression, nutrigenomics allows healthcare professionals to understand genetic strengths and weaknesses, making specific recommendations that help achieve better health outcomes for patients.

The parties will collaborate with a view to improving the awareness and understanding in the market of nutrigenomic testing, including the publication of educational materials and scientific studies. The report, which is intended to be utilised by healthcare professionals and their patients, will be designed to meet Omega’s specific requirements while incorporating the current data and structure of the software provider’s existing reports.

This Agreement follows on from the microbiome testing partnership which was announced on 26 October 2022 and, once completed, will conclude the Company’s initial product range expansion as previously set out in the Company’s strategic plan.

**Jag Grewal, CEO of Omega Diagnostics said:** *“We are pleased to have signed this second strategic partnership, this time with a leading nutrigenomics software provider, which will give the Company a broader and complementary range of tests to help manage gut health and improve patient outcomes for those living with chronic diseases. Our focus remains on commercial and service development within the sector, as we seek to grow revenues and further consolidate our established market leading position, thus enabling the Board’s vision of delivering personalised nutrition for better health.”*

**Contacts:**

**Omega Diagnostics Group PLC**

Jag Grewal, Chief Executive Officer  
Chris Lea, Chief Financial Officer

[www.omegadx.com](http://www.omegadx.com)

via Walbrook PR

**finnCap Ltd**

Geoff Nash/Edward Whiley/George Dollemore (Corporate Finance)  
Alice Lane/Charlotte Sutcliffe (ECM)

Tel: 020 7220 0500

**Walbrook PR Limited**

Paul McManus / Sam Allen / Lianne Applegarth

Tel: 020 7933 8780 or [omega@walbrookpr.com](mailto:omega@walbrookpr.com)  
Mob: 07980 541 893 / 07502 558 258 / 07584 391 303

**About Omega Diagnostics Group PLC**

Omega (AIM: ODX) is a specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition.

[www.omegadx.com](http://www.omegadx.com)